News Snapshot:
HONG KONG, Sept. 23, 2021 / [PRNewswire](//stocksnewsfeed.com/category/pr-newswire/) / — On September 24, Broncus (02216.HK), a pioneer in the field of interventional pulmonology in China, was successfully listed on the main board of the Hong Kong [Stock](//stocksnewsfeed.com/) Exchange. Broncus, founded in 2012, is a medical device company focused on the development of interventional pulmonology products and a pioneer in the field of interventional pulmonology, providing innovative lung solutions in China and globally. Leveraging its whole lung access navigation technology and encompassing navigation, diagnosis and treatment, its integrated interventional pulmonology platform addresses the pain points of the existing diagnosis and treatment paradigms...
